These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 26892147

  • 1. Arsenic trioxide augments all-trans retinoic acid-induced differentiation of HL-60 cells.
    Sumi D, Suzukawa K, Himeno S.
    Life Sci; 2016 Mar 15; 149():42-50. PubMed ID: 26892147
    [Abstract] [Full Text] [Related]

  • 2. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
    Jung YS, Cheong HJ, Kim SJ, Kim KH, Lee N, Park HS, Won JH.
    Leuk Res; 2014 Aug 15; 38(8):977-82. PubMed ID: 24953245
    [Abstract] [Full Text] [Related]

  • 3. Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A.
    Iriyama N, Yuan B, Hatta Y, Horikoshi A, Yoshino Y, Toyoda H, Aizawa S, Takeuchi J.
    Oncol Rep; 2012 Nov 15; 28(5):1875-82. PubMed ID: 22940758
    [Abstract] [Full Text] [Related]

  • 4. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid.
    Wang G, Li W, Cui J, Gao S, Yao C, Jiang Z, Song Y, Yuan CJ, Yang Y, Liu Z, Cai L.
    Hematol Oncol; 2004 Jun 15; 22(2):63-71. PubMed ID: 15468344
    [Abstract] [Full Text] [Related]

  • 5. Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells.
    Nayak S, Shen M, Bunaciu RP, Bloom SE, Varner JD, Yen A.
    Leuk Lymphoma; 2010 Sep 15; 51(9):1734-47. PubMed ID: 20615082
    [Abstract] [Full Text] [Related]

  • 6. Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells.
    Valenzuela M, Glorieux C, Stockis J, Sid B, Sandoval JM, Felipe KB, Kviecinski MR, Verrax J, Buc Calderon P.
    Br J Cancer; 2014 Aug 26; 111(5):874-82. PubMed ID: 25003661
    [Abstract] [Full Text] [Related]

  • 7. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
    Coltella N, Valsecchi R, Ponente M, Ponzoni M, Bernardi R.
    Clin Cancer Res; 2015 Aug 15; 21(16):3685-94. PubMed ID: 25931453
    [Abstract] [Full Text] [Related]

  • 8. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis.
    Wang H, Chen XY, Wang BS, Rong ZX, Qi H, Chen HZ.
    Leuk Res; 2011 Sep 15; 35(9):1170-7. PubMed ID: 21774985
    [Abstract] [Full Text] [Related]

  • 9. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
    Raffoux E, Rousselot P, Poupon J, Daniel MT, Cassinat B, Delarue R, Taksin AL, Réa D, Buzyn A, Tibi A, Lebbé G, Cimerman P, Chomienne C, Fermand JP, de Thé H, Degos L, Hermine O, Dombret H.
    J Clin Oncol; 2003 Jun 15; 21(12):2326-34. PubMed ID: 12805334
    [Abstract] [Full Text] [Related]

  • 10. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
    Zhou GB, Zhang J, Wang ZY, Chen SJ, Chen Z.
    Philos Trans R Soc Lond B Biol Sci; 2007 Jun 29; 362(1482):959-71. PubMed ID: 17317642
    [Abstract] [Full Text] [Related]

  • 11. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
    Chen L, Wang J, Hu X, Xu X.
    Hematology; 2014 Jun 29; 19(4):202-7. PubMed ID: 24074286
    [Abstract] [Full Text] [Related]

  • 12. Arsenic trioxide suppresses transcription of hTERT through down-regulation of multiple transcription factors in HL-60 leukemia cells.
    Zhang Y, Sun M, Shi W, Yang Q, Chen C, Wang Z, Zhou X.
    Toxicol Lett; 2015 Jan 22; 232(2):481-9. PubMed ID: 25436934
    [Abstract] [Full Text] [Related]

  • 13. Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo.
    Atashrazm F, Lowenthal RM, Dickinson JL, Holloway AF, Woods GM.
    Oncotarget; 2016 Jul 19; 7(29):46028-46041. PubMed ID: 27329592
    [Abstract] [Full Text] [Related]

  • 14. Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.
    Rock N, Mattiello V, Judas C, Huezo-Diaz P, Bourquin JP, Gumy-Pause F, Ansari M.
    Pediatr Hematol Oncol; 2014 Mar 19; 31(2):143-8. PubMed ID: 24498972
    [Abstract] [Full Text] [Related]

  • 15. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
    Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y, Huang J, Jin J.
    Hematol Oncol; 2014 Mar 19; 32(1):40-6. PubMed ID: 23963734
    [Abstract] [Full Text] [Related]

  • 16. Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada.
    Lachaine J, Mathurin K, Barakat S, Couban S.
    Eur J Haematol; 2015 Sep 19; 95(3):218-29. PubMed ID: 25354894
    [Abstract] [Full Text] [Related]

  • 17. New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach.
    Zeidan AM, Gore SD.
    Clin Cancer Res; 2014 Oct 01; 20(19):4985-93. PubMed ID: 25274377
    [Abstract] [Full Text] [Related]

  • 18. Contemporary treatment of APL.
    Cull EH, Altman JK.
    Curr Hematol Malig Rep; 2014 Jun 01; 9(2):193-201. PubMed ID: 24643310
    [Abstract] [Full Text] [Related]

  • 19. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
    Quezada G, Kopp L, Estey E, Wells RJ.
    Pediatr Blood Cancer; 2008 Jul 01; 51(1):133-5. PubMed ID: 18293388
    [Abstract] [Full Text] [Related]

  • 20. Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1β.
    Dunoyer-Geindre S, Rivier-Cordey AS, Tsopra O, Lecompte T, Kruithof EKO.
    Ann Hematol; 2017 Jun 01; 96(6):905-917. PubMed ID: 28343272
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.